Pending European Commission approval, AYVAKYT will become the first and only therapy for people living with ISM in Europe. "Indolent systemic mastocytosis is often characterized by severe symptoms ...

CAMBRIDGE, Mass., Sept. 25, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomicall ...

Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

European regulators have recommended a licence for Blueprint Medicines’ Ayvakyt (avapritinib), for adults with stomach tumours with certain mutations. Blueprint specialises in drugs that tackle ...

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses ...

CAMBRIDGE, Mass., March 3, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the European Medicines Agency (EMA) has validated the company's Type II ...

Blueprint Medicines Corp.’s cancer drug Ayvakyt (avapritinib) looks set to gain an expanded label in Europe, amid a flurry of decisions from the European Medicines Agency’s CHMP scientific committee.

Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the third quarter ended Sept 30, 2024, and provided updated financial guidance.

CAMBRIDGE, Mass., May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2025 ...

--Blueprint Medicines Corporation today announced the European Commission has approved AYVAKYT ® for the treatment of adult patients with indolent systemic mastocytosis with moderate to severe ...

AYVAKYT® (avapritinib) is a kinase inhibitor approved by the European Commission for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an ...

-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis -- CAMBRIDGE, Mass ...